<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01455025</url>
  </required_header>
  <id_info>
    <org_study_id>Primal study</org_study_id>
    <nct_id>NCT01455025</nct_id>
  </id_info>
  <brief_title>Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia</brief_title>
  <acronym>PRIMAL</acronym>
  <official_title>A Phase 1, Dose Escalation Study of Plerixafor in Combination With Induction and Consolidation Chemotherapy in Patients With Relapsed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acute Leukemia French Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, dose escalation study of Plerixafor in combination with granulocyte-colony&#xD;
      stimulating factor , Daunorubicin and Cytarabine in adults patients with relapsed acute&#xD;
      myeloid leukemia .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Primary objective is to determine the maximal tolerated dose and Recommended Phase 2 Dose&#xD;
      of plerixafor when used in combination with granulocyte-colony stimulating factor,&#xD;
      Daunorubicin and Cytarabine during induction therapy Then determine the tolerability of&#xD;
      plerixafor administered in combination with G-CSF and cytarabine during consolidation&#xD;
      therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    no recruitment on time&#xD;
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximal tolerated dose</measure>
    <time_frame>40 days</time_frame>
    <description>4 steps of plerixafor doses from 240 to 480 microgram per kilogram per day concomitant with granulocyte-colony stimulating factor and chemotherapy Three to 6 evaluable patients will be enrolled at each dose level in a modified 3 + 3 design.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability of plerixafor in combination with granulocyte-colony stimulating factor and chemotherapy</measure>
    <time_frame>9 months</time_frame>
    <description>Number of Adverse Events and Serious Adverse Events :examined at each dose level by the Independent Data safety Monitoring Board</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of plerixafor on leukemic blasts</measure>
    <time_frame>10 Days</time_frame>
    <description>study of the drop of leukemic blasts blood rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of combination plerixafor with granulocyte-colony stimulating factor, Daunorubicin and Cytarabine</measure>
    <time_frame>2 months</time_frame>
    <description>-Minimal Residual Disease level after first consolidation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of combination plerixafor with granulocyte-colony stimulating factor, Daunorubicin and Cytarabine</measure>
    <time_frame>5 weeks</time_frame>
    <description>- Time to remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of combination plerixafor with granulocyte-colony stimulating factor, Daunorubicin and Cytarabine</measure>
    <time_frame>3 months</time_frame>
    <description>-Rate of patients able to proceed to hematopoietic stel cell transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of combination plerixafor with granulocyte-colony stimulating factor, Daunorubicin and Cytarabine</measure>
    <time_frame>9 months</time_frame>
    <description>-disease free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of combination plerixafor with granulocyte-colony stimulating factor, Daunorubicin and Cytarabine</measure>
    <time_frame>9 months</time_frame>
    <description>-event free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of combination plerixafor with granulocyte-colony stimulating factor, Daunorubicin and Cytarabine</measure>
    <time_frame>9 months</time_frame>
    <description>overal survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Plerixafor granulocyte-colony stimulating factor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 steps of plerixafor doses from 240 to 480 microgram/kg per day concomitant with GCSF and chemotherapy 3 to 6 evaluable patients will be enrolled at each dose level in a modified 3 + 3 design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor granulocyte-colony stimulating factor</intervention_name>
    <description>Induction phase Plerixafor IV from D1 to D3 and from D8 to D10, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D10, Intravenous daunorubicin 60 mg/m2/day from D1 to D3 Cytarabine 500 mg/m2/day continuous infusion over 24h from D1 to D3 followed by cytarabine 2-hour bolus of 1000 mg/m2/12h from D8 to D10.&#xD;
Consolidation phase Plerixafor at D1, D3 and D5, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D5, Cytarabine continuous infusion of 3-h bolus of 3000 mg/m2/12h D1, D3 and D5</description>
    <arm_group_label>Plerixafor granulocyte-colony stimulating factor</arm_group_label>
    <other_name>Plerixafor G CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Acute Myeloid Leukemia in first relapse with first response duration &gt; 9&#xD;
             months.&#xD;
&#xD;
          -  Age between 18 and 65 years.&#xD;
&#xD;
          -  Treatment with hydroxyurea or purinethol is allowed if discontinued at least 24 hours&#xD;
             before the start of study treatment.&#xD;
&#xD;
          -  White blood count less than 30 x 109/L&#xD;
&#xD;
          -  Left ventricular ejection fraction more than 50% on echocardiography or multigated&#xD;
             acquisition scan or similar radionuclide angiographic scan.&#xD;
&#xD;
          -  Total bilirubin less than 1.5 x upper limit of normal= ULN or AST and ALT less than&#xD;
             2.5 x ULN or gammaGT less than 2.5 x ULN.&#xD;
&#xD;
          -  Serum creatinine less than 1.5 x ULN and/or creatinine clearance more than 50 ml/mn.&#xD;
&#xD;
          -  ECOG performance status less than 2&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule.&#xD;
&#xD;
          -  Absence of pregnancy or lactation&#xD;
&#xD;
          -  Affiliated to French social security system or similar&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AML evolving from MPD and/or secondary AML&#xD;
&#xD;
          -  Patients treated with more than 270 mg/m2 of daunorubicin during first line therapy.&#xD;
&#xD;
          -  Have any of the following within the last 9 months :&#xD;
&#xD;
          -  Unstable supraventricular arrhythmia or patient with a pace-maker&#xD;
&#xD;
          -  Any ventricular arrhythmia&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Myocardial infarction, ischemia, stable coronary disease or angina pectoris&#xD;
&#xD;
          -  Syncope with a known cardiovascular etiology&#xD;
&#xD;
          -  Known hypersensitivity or contra-indication to drugs used in the protocol = G-CSF,&#xD;
             daunorubicin, cytarabine or to excipients.&#xD;
&#xD;
          -  Previous treatment with plerixafor.&#xD;
&#xD;
          -  Previous hematopoietic stem cell transplantation = Allologous or autologous.&#xD;
&#xD;
          -  White blood count more than 30 x 109/L despite treatment with hydroxyurea or&#xD;
             purinethol.&#xD;
&#xD;
          -  Treatment with chemotherapy or G-CSF within 3 months of screening.&#xD;
&#xD;
          -  Uncontrolled active infection.&#xD;
&#xD;
          -  Uncontrolled arrythmia&#xD;
&#xD;
          -  Grade more than 3 renal dysfunction with serum creatinine more than 1.5 x ULN and/or&#xD;
             creatinine clearance less than 50 ml/mn.&#xD;
&#xD;
          -  Significant neurologic grade more than 2 or psychiatric disorder, dementia or&#xD;
             seizures.&#xD;
&#xD;
          -  Clinical symptoms suggesting active central nervous system leukemia.&#xD;
&#xD;
          -  Pre-existing disorder predisposing the patient to serious or life-threatening&#xD;
             infections = cystic fibrosis, congenital or acquired immunodeficiency, bleeding&#xD;
             disorder or cytopenia&#xD;
&#xD;
          -  Thrombocytopenia refractory to platelet transfusion&#xD;
&#xD;
          -  Anticoagulant therapy&#xD;
&#xD;
          -  Severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia&#xD;
             or shock or disseminated intravascular coagulation.&#xD;
&#xD;
          -  Thrombocytopenia refractory to platelet transfusion.&#xD;
&#xD;
          -  Prior total body irradiation more than 10 Gy.&#xD;
&#xD;
          -  Known HIV, Hepatitis B or C positivity.&#xD;
&#xD;
          -  Participation into a clinical study of an investigational agent within 14 days before&#xD;
             study entry.&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Adult patient protected by law&#xD;
&#xD;
          -  Concurrent treatment with any other anti-cancer therapy except hydroxyurea&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier THOMAS, MD PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ALFA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Didier BOUSCARY, MD PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xavier THOMAS</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO website</description>
  </link>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>June 24, 2011</study_first_submitted>
  <study_first_submitted_qc>October 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2011</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plerixafor granulocyte-colony stimulating factor</keyword>
  <keyword>Chemotherapy in relapse</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plerixafor</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

